McKesson Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for McKesson Corporation for the quarter ended June 30, 2008 (Fiscal Year 2009, Q1). McKesson operates in two primary segments: Distribution Solutions (pharmaceutical, medical-surgical, and health/beauty distribution) and Technology Solutions (software and services for healthcare). The company is a large accelerated filer incorporated in Delaware.
Key Financial Metrics
| Metric | Q1 2009 (Jun 30, 2008) | Q1 2008 (Jun 30, 2007) |
|---|---|---|
| Revenues | $26,704 million | $24,528 million |
| Gross Profit | $1,268 million | $1,177 million |
| Operating Income | $371 million | $356 million |
| Net Income | $235 million | $235 million |
| Diluted EPS | $0.83 | $0.77 |
| Operating Cash Flow | $314 million | $432 million |
| Cash and Equivalents | $1,187 million | $2,203 million (end of period) |
| Long-Term Debt | $1,794 million | $1,795 million |
| Working Capital | $2,314 million | $2,438 million |
Margins: Gross profit margin was 4.75% (down 5 basis points from 4.80%). Operating margin was approximately 1.39%.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 9% to $26.7 billion, driven primarily by the Distribution Solutions segment (up 9%). U.S. pharmaceutical direct distribution grew 16%, while sales to customers' warehouses declined 8% due to volume shifts and customer consolidation.
- Profitability: Net income remained flat at $235 million year-over-year. However, Diluted EPS increased 8% to $0.83, primarily due to a 7% reduction in weighted average shares outstanding from aggressive stock repurchases.
- Segment Performance:
- Distribution Solutions: Operating profit increased 13% to $384 million, aided by higher buy-side margins and generic drug sales.
- Technology Solutions: Operating profit decreased 34% to $66 million. This decline was largely due to the recognition of $21 million in deferred disease management revenues in the prior year (where expenses were previously recognized) and a change in product mix.
- Cash Flow: Operating cash flow decreased to $314 million from $432 million. This was impacted by increased investment in net financial inventory and receivables to support revenue growth, partially offset by the accelerated receipt of $325 million via the accounts receivable sales facility.
- Acquisitions: The company acquired McQueary Brothers Drug Company for approximately $190 million in May 2008, funded by cash on hand.
Guidance, Outlook, and Risks
- Capital Allocation: The Board approved a new $1.0 billion stock repurchase plan in April 2008. As of June 30, 2008, $1.184 billion remained available. The quarterly dividend was increased from $0.06 to $0.12 per share.
- Tax Outlook: The company anticipates recognizing $65 million of previously unrecognized tax benefits and related interest expense in the second quarter of 2009 following the settlement of uncertain tax positions.
- Liquidity: The company renewed its accounts receivable sales facility, increasing the committed balance to $1.0 billion. It maintains a $1.3 billion revolving credit facility with no outstanding balance as of June 30, 2008.
- Legal Proceedings: Significant litigation includes the "New England Carpenters I" class action regarding drug pricing, with a trial date set for December 1, 2008. Proposed settlements involving co-defendants First DataBank and Medi-Span are pending final court approval. New actions were filed in California and Connecticut alleging RICO and antitrust violations.
- Risk Factors: Key risks include changes in the U.S. healthcare regulatory environment, drug price inflation/deflation, customer concentration, and the integration of strategic acquisitions.
Investor Verification Checklist
- Share Count Impact: Verify the sustainability of EPS growth given the heavy reliance on share repurchases (2 million shares repurchased in Q1 2009) versus flat net income.
- Working Capital Trends: Monitor the increase in "net financial inventory" (inventory net of payables) and receivables, which reduced operating cash flow despite revenue growth.
- Technology Segment Volatility: Assess the impact of the $21 million deferred revenue recognition in the prior year on the Technology Solutions segment's comparability and future margin stability.
- Legal Exposure: Track the status of the "New England Carpenters I" trial and the new RICO actions in California and Connecticut, as unfavorable outcomes could result in substantial damages.
- Tax Settlement: Confirm the timing and impact of the anticipated $65 million tax benefit recognition in Q2 2009.